Literature DB >> 21923663

Tetanus in patients with chronic wounds - are we aware?

Elizabeth Farnworth1, Awen Roberts, Aravindan Rangaraj, Uzma Minhas, Samantha Holloway, Keith Harding.   

Abstract

The incidence of tetanus in patients with wounds is unknown; however, recently concern has been raised over the proportion of tetanus cases in which a chronic wound is the portal of entry for Clostridium tetani. Varicose ulcers, dermatosis and necrosed tumours are estimated to be the point of entry for C. tetani spores in 11-14% of three cases. Of diabetic patients in the USA who contracted tetanus, a diabetic foot ulcer was responsible in 25% of cases despite this chronic wounds have yet to be considered as a risk factor for tetanus. An audit was undertaken and a survey devised to form the basis of the data collection to assess if patients with chronic wounds are up-to-date in accordance with the tetanus immunisation programme. Over a 5-day period, the data were prospectively collected and the tetanus status of a 100 patients retrospectively analysed. The status was then compared with general practitioner (GP) records via telephone follow-up. One hundred patients (n = 100) were available in the audit period, with the majority being male (n = 51). The age range was 22-91 years old (median 70 years). Nearly half of the samples (n = 48) were diabetic, with the majority of patients (n = 35) having venous leg ulcers. Only 15% had a biopsy of their wound. The duration of wounds varied from 1 to 480 months. Patients were asked to confirm their tetanus status. Almost half of the patients were unsure of their tetanus status 48% (n = 48), almost a third 30% (n = 30) thought they were not covered and 22% (n = 22) thought they were up-to-date. After confirming with the GP records, the results were as follows: almost half of the patients, 43% (n = 43) were not covered, 33% (n = 33) were up-to-date, 13% had no immunisation records available at the GPs, 10% had no GP contact details and 1% no contact was possible. Currently, tetanus prophylaxis is given based on the vaccination history of the patient but as identified that this can prove to be unreliable. With the burden of chronic wound and ageing population set to increase, levels of protection amplify the risk of tetanus faced by those suffering from chronic wounds. Strict caution should be taken in those patients who were born before the national childhood vaccination programme, implemented in 1961. Moreover, every effort should be made to ensure that such individuals complete their primary course. By ensuring each patient is actively immunised, protection against tetanus, a potential killer, is provided.
© 2011 The Authors. © 2011 Blackwell Publishing Ltd and Medicalhelplines.com Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21923663      PMCID: PMC7950768          DOI: 10.1111/j.1742-481X.2011.00850.x

Source DB:  PubMed          Journal:  Int Wound J        ISSN: 1742-4801            Impact factor:   3.315


  24 in total

Review 1.  Tetanus: a review of the literature.

Authors:  T M Cook; R T Protheroe; J M Handel
Journal:  Br J Anaesth       Date:  2001-09       Impact factor: 9.166

2.  Immunity to diphtheria and tetanus in England and Wales.

Authors:  P A Maple; C S Jones; E C Wall; A Vyseb; W J Edmunds; N J Andrews; E Miller
Journal:  Vaccine       Date:  2000-09-15       Impact factor: 3.641

3.  [Tetanus in a man presenting with a chronic wound].

Authors:  Sabine Texier; Marion Dermu
Journal:  Presse Med       Date:  2004-06-19       Impact factor: 1.228

4.  Tetanus in the elderly--An important preventable disease in Australia.

Authors:  Helen E Quinn; Peter B McIntyre
Journal:  Vaccine       Date:  2006-10-12       Impact factor: 3.641

Review 5.  Tetanus prophylaxis for diabetic foot ulcers.

Authors:  Lee C Rogers; Robert G Frykberg
Journal:  Clin Podiatr Med Surg       Date:  2006-10       Impact factor: 1.231

6.  Tetanus--forgotten but not gone.

Authors:  J P Sanford
Journal:  N Engl J Med       Date:  1995-03-23       Impact factor: 91.245

7.  Impaired immunity against tetanus in type 2 diabetes.

Authors:  Ali Tamer; Oguz Karabay; Hasan Ekerbicer; Mustafa Tahtaci; Belgin Selam; Harika Celebi
Journal:  Med Sci Monit       Date:  2005-11-24

8.  Immunologic response to tetanus toxoid in the elderly: one-year follow-up.

Authors:  K Alagappan; W Rennie; D Lin; C Auerbach
Journal:  Ann Emerg Med       Date:  1998-08       Impact factor: 5.721

9.  Insufficient tetanus vaccination status in patients with chronic leg ulcers. Results of a prospective investigation in 100 patients.

Authors:  A Korber; N Graue; J Rietkotter; E Kreuzfelder; S Grabbe; J Dissemond
Journal:  Dermatology       Date:  2008-04-21       Impact factor: 5.366

10.  The prevalence of chronic lower-limb ulceration has been underestimated: results of a validated population questionnaire.

Authors:  O Nelzén; D Bergqvist; A Lindhagen
Journal:  Br J Surg       Date:  1996-02       Impact factor: 6.939

View more
  4 in total

Review 1.  Do patients with diabetic foot ulcer need booster dose of tetanus vaccine?

Authors:  Zahra Hoseini Tavassol; Zahra Sajjadpour; Shirin Hasani-Ranjbar; Mahnaz Pejman Sani; Hamidreza Aghaei Meybodi; Bagher Larijani
Journal:  J Diabetes Metab Disord       Date:  2022-01-30

2.  Treatment preferences in Turkey for open fracture of the tibial diaphysis.

Authors:  Güzelali Özdemir; Barış Yılmaz; Baran Kömür; Evrim Şirin; Nazım Karahan; Erman Ceyhan
Journal:  Acta Orthop Traumatol Turc       Date:  2017-01-26       Impact factor: 1.511

Review 3.  Non-surgical treatment of tetanus infection associated with breast cancer skin ulcer: a case report and literature review.

Authors:  Kazuhito Nomura; Eiji Sakawaki; Sonoko Sakawaki; Ayumu Yamaoka; Wakiko Aisaka; Hiroyuki Okamoto; Yoshihiro Takeyama; Shuji Uemura; Eichi Narimatsu
Journal:  BMC Infect Dis       Date:  2021-01-07       Impact factor: 3.090

4.  Severe tetanus following ulcerated skin cancer: Case report.

Authors:  Jin Wang; Ying Yang; Chao Yang; Wen Lv; Shihai Xu; Fei Shi; Aijun Shan
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.